Skip to content

TO Find the Effect of Codyceps Tablet as Nutritional Supplement

Clinical Study to Evaluate the Efficacy and Safety of Cordyceps Tablet (Cordyceps Sinensis) as a Nutritional Supplement in Patients with Co morbidities

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/040784
Enrollment
24
Registered
2022-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E089- Diabetes mellitus due to underlying condition without complications

Interventions

None listed

Sponsors

DXN Manufacturing India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants aged 18-60 years (both sex). 2. Participants who are presenting with any one of the co morbidities like Systemic hypertension or Diabetes Mellitus or Hyperlipidemia.

Exclusion criteria

Exclusion criteria: 1. Participants presenting with fever and acute infections, will be excluded. 2. History of heart, liver or kidney failure. 3. Allergy or intolerance to the individual constituents in test product. 4. Patients with history of abnormal thyroid 5. Patients with history of any malignancy. 6. History of any Neurodegenerative disease 7. Organ transplantation 8. Allergy to fungi 9. Subjects who are pregnant and lactating mothers, or with any serious disease condition limiting full adhesion to the protocol. 10. Participation in an investigational drug trial in the 30 days prior to the screening visit.

Design outcomes

Primary

MeasureTime frame
1.Improvement in the nutritional status based on Malnutrition screening tool, Mini Nutritional assessment & Determine nutritional health checklist. [Baseline & week 4] 2.Improvement in Cognitive function by using Montreal Cognitive Assessment [Baseline & week 4]Timepoint: Day 0 and 28

Secondary

MeasureTime frame
1.Improvement in BMI and mid arm circumference and Various hematological and biochemical blood parameter will be monitored 2.Adverse event monitoringTimepoint: Day 0 and 28

Countries

India

Contacts

Public ContactDr Vivek MBBS MS

Ki3, CRO

drvivekcro@gmail.com9176054266

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026